Conditional ectopic expression of C/EBP beta in NIH-3T3 cells induces PPAR gamma
and stimulates adipogenesis.
The general consensus is that cold stimulates a greater release of catecholamines by the nervous system, an event that stimulates thermogenesis through the activation of protein kinase A (PKA) and p38 mitogen-activated protein kinases (p-38 MAPK) pathways followed by the activation of uncoupling protein 1 (UCP1) and phosphorylation of the specific factors PPAR gamma
coactivator 1 alpha (PGC-1[alpha]), cAMP response element-binding protein (cReB), and activating transcription factor 2 (ATF2) [14,15, 44, 45].
Gene expression changes induced by PPAR gamma
agonists in animal and human liver.
However this is not as good as TZD that enhanced the activity of PPAR[gamma]-dependent luciferase and improves glycaemic control in patient with Type 2 diabetes via improving insulin sensitivity through its action at PPAR gamma
1 and PPAR gamma
Growth arrest (40%) and PPAR gamma
mRNA and protein upregulation was achieved with gamma-tocopherol within 6 h.
Activation of PPAR gamma
may mediate a portion of the anticancer activity of conjugated linoleic acid.
NIDA is funding substantially all costs of these studies, which are evaluating the effects of PPAR gamma
agonists on oxycontin and heroin use.
The PAX8/ PPAR gamma
fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma.
For the study, the researchers introduced MCPIP to living cells from mice that had been stripped of the PPAR gamma
gene and found that the cells still completed the developmental process necessary to build fat.
By activating PPAR gamma
in adipocytes, Paractin may help maintain healthy blood sugar levels.
Muraglitazar could become the first in a new class of compounds that simultaneously activates both peroxisome proliferator activated receptors (PPARs), known as PPAR alpha and PPAR gamma
with overexpresssion of HER2/neu or overexpression of epidermal growth factor receptor, are treated with strongly binding PPAR gamma
ligands, and patients affected with cancer associated with overexpression of at least one member of the class I family of receptor tyrosine kinases selected from the group consisting of HER-2/neu and epidermal growth factor rector, comprising administering to said patient a therapeutically effective amount of a ligand of peroxisome proliferator-activated receptor gamma (PPAR gamma
) which has a pKi of at least 4.